Key result
Higher polygenic risk scores fail to modulate CAD risk in familial hypercholesterolemia.
Cohort (n=2,289)
Answers are grounded in this paper and cite their sources.
Background and aims: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of LDL-C leading to premature cardiovascular disease (CAD). Only about 40% of individuals with a clinical diagnosis of FH have a causative genetic variant identified, and a proportion of genetically negative cases may have a polygenic cause rather than a still unidentified monogenic cause. This work aims to evaluate and validate the role of a polygenic risk score (PRS) associated with hypercholesterolemia in a Brazilian FH cohort and its clinical implications. Methods: We analyzed a previously derived PRS of 12 and 6 SNPs (Single Nucleotide Polymorphism) in 684 FH individuals (491 mutation-negative [FH/M-], 193 mutation-positive [FH/M+]) and in 1605 controls. Coronary artery calcium (CAC) score was also evaluated. Both scores were also higher in the FH/M+ group (36.48 and 26.26, respectively) when compared to the control group (p < 0.001 for the two scores) but inferior to the FH/M- group. Within FH individuals, the presence of a higher PRS score was not associated with LDL-C levels or with CAD risk. Conclusion: A higher PRS is associated with significantly higher levels of LDL-C and it is independently associated with higher CAC in the Brazilian general population. A polygenic cause can explain a fraction of FH/M- individuals but does not appear to be a modulator of the clinical phenotype among FH individuals, regardless of mutation status.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2022) conducted a cohort in Familial hypercholesterolemia (FH) (n=2,289). Polygenic risk score (PRS) of 12 and 6 SNPs vs. Controls (general population) and different mutation status groups was evaluated on Polygenic risk score values between groups and association with LDL-C, CAD risk, and CAC score (p=<0.001). Higher polygenic risk scores were found in mutation-positive familial hypercholesterolemia patients compared to controls, but the score did not modulate CAD risk among FH individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: